Natural Disease Course in Usher Syndrome Patients Harboring USH2A Variant p.Cys870* in Exon 13, Amenable to Exon Skipping Therapy
Genes · 2023
DOI: 10.3390/genes14030652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Katja Čadonič und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eye Hospital, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Usher Syndromes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian research agency (ARRS).
Abstract (Originalsprache)
The aim of the study was to determine the rate of retinal degeneration in patients with c.2610C>A (p.Cys870*) in USH2A exon 13, amenable to exon skipping therapy. There were nine patients from seven families, three of whom were male (two were homozygous). Seven patients had follow-up data (median of 11 years). Analysis included best corrected visual acuity (BCVA, decimal Snellen), visual field (Goldmann perimetry target II/4), fundus autofluorescence (FAF), optical coherence tomography (OCT), and microperimetry (MP). The median age at the onset of nyctalopia was 20 years (range, 8–35 years of age). At the first exam, at a median age of 42 years, the median BCVA was 0.5 (0.2–1.0), and the median visual field diameter was 23° (5°–114°). Imaging showed a hyperautofluorescent ring delineating preserved foveal photoreceptors in 78% (7/9) of patients, while 22% (2/9) had a hyperautofluorescent patch or atrophy, reflecting advanced disease. Survival analysis predicted that 50% of patients reach legal blindness based on a visual field diameter < 20° at the age of 52 (95% CI, 45–59) and legal blindness based on a BCVA ≤ 0. 1 (20/200) at the age of 55 (95% CI, 46–66). Visual field constriction occurred at the median rate of radial 1.5 deg/year, and hyperautofluorescent ring constriction occurred at the median rate of 34 μm/year. A non-null second allele was found in two patients: p.Thr4315Pro and p.Arg303His; the patient with p.Arg303His had a milder disease. The rates of progression will be useful in the design and execution of clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Hospital, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
ORCID-Profile: Jana Sajovic
Förderung
- Slovenian research agency (ARRS)
Zitieren
APA
Čadonič, K., Sajovic, J., Hawlina, M., & Fakin, A. (2023). Natural Disease Course in Usher Syndrome Patients Harboring USH2A Variant p.Cys870* in Exon 13, Amenable to Exon Skipping Therapy. Genes. https://doi.org/10.3390/genes14030652
Vancouver
Čadonič K, Sajovic J, Hawlina M, Fakin A. Natural Disease Course in Usher Syndrome Patients Harboring USH2A Variant p.Cys870* in Exon 13, Amenable to Exon Skipping Therapy. Genes. 2023. doi:10.3390/genes14030652
BibTeX
@article{adoni2023,
author = {Čadonič, Katja and Sajovic, Jana and Hawlina, Marko and Fakin, Ana},
title = {Natural Disease Course in Usher Syndrome Patients Harboring USH2A Variant p.Cys870* in Exon 13, Amenable to Exon Skipping Therapy},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14030652}
}
EUVIMED